Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Dr Reddy’s Laboratories ( (RDY) ) has issued an announcement.
On June 11, 2025, Dr. Reddy’s Laboratories announced its participation in an investor conference organized by CLSA, scheduled for June 18, 2025, in Hyderabad. This meeting, intended for institutional investors, underscores the company’s ongoing efforts to engage with stakeholders and provide insights into its operations and strategic direction.
The most recent analyst rating on (RDY) stock is a Buy with a $17.40 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
Dr Reddy’s Laboratories receives a solid overall score due to its strong financial performance, especially in revenue growth and balance sheet stability. Technical indicators show positive momentum, although the stock is below its long-term average. Valuation is reasonable, but dividend yield is low. The recent earnings call was positive, highlighting growth and strategic advancements despite some market challenges.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories is a prominent pharmaceutical company based in Hyderabad, India. It specializes in the development and production of a wide range of pharmaceutical products, focusing on generic medications and active pharmaceutical ingredients. The company is listed on major stock exchanges including the National Stock Exchange of India, BSE Limited, and the New York Stock Exchange.
Average Trading Volume: 2,121,312
Technical Sentiment Signal: Strong Buy
Current Market Cap: $13.16B
Learn more about RDY stock on TipRanks’ Stock Analysis page.